PhaseBio - An Open Label Phase 2 Study to Assess the Safety Tolerability and Efficacy of a Sustained-Release VIP Analogue PB1046 Following 16 Weeks of Once Weekly Subcutaneous Injections in Adult Subjects with Symptomatic Pulmonary Arterial Hypertensi
Brief description of study
The purpose of this research study is to test an experimental drug called PB1046. The study will examine the safety, tolerability and efficacy of Sustained-Release VIP Analogue, PB1046 in people who have Pulmonary Arterial Hypertension (PAH).
Clinical Study Identifier: s18-01242
ClinicalTrials.gov Identifier: NCT03556020
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.